HealthDay on MSN7h
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast CancerFor patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
A team led by the Institute for Bioengineering of Catalonia (IBEC) and the Hospital del Mar Research Institute has developed ...
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for ...
Q4 2024 Management View CEO Pascal Soriot highlighted a strong 2024 performance with total revenue up 21% and core EPS growth at 19%, reflecting solid business momentum supported by pipeline ...
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan ...
As global markets navigate a period of volatility marked by AI competition concerns and fluctuating interest rates, the technology sector remains in sharp focus, with the Nasdaq Composite experiencing ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback